Eligible patients could enroll into this continuation study directly after completing the 6-month extension study.
Baseline demographic and clinical characteristics for patients in the current continuation study are summarized in Table 1.
After 6 months of extension treatment (Baseline of the current continuation study), the mean CGI-BP-S score was 2.1.
Prior to entering the current 18-month continuation study, an informed consent form was reviewed and signed by all patients.
The mean dose of lurasidone during the 18-month continuation study was 61.8 mg/day, and the modal dose was 60 mg/day.
A total of 122/559 patients (21.8%) provided informed consent and entered the current 18-month continuation study, of whom 40/122 (32.8%) were completers (Fig. 1).
This paper acts as continuation study using the hypotheses from the author's previous research on the same topic to validate the hypotheses.
The safety population consisted of all patients who received at least one dose of lurasidone in the 18-month continuation study that followed the initial 6-week double-blind study and the subsequent 6-month open-label extension study.
In a continuation study, we plan to conduct a real-life assessment related to forest bioeconomy activity and apply this study as the core for our indicators and tools to assess its sustainability.
